Collection of Blood From Patients With Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00923221|
Recruitment Status : Recruiting
First Posted : June 18, 2009
Last Update Posted : May 20, 2022
- It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
- Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
- Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
-All patients participating in NCI prostate cancer protocols.
- Patients with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
- Blood samples are collected at the initial visit or at follow-up visits.
- DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
- Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
|Condition or disease|
|Cancer Of Prostate Prostate Cancer Prostatic Neoplasms Metastatic Prostate Cancer Prostate|
-To obtain blood samples from patients with prostate cancer for genotyping analyses.
- All patients seen in the NCI prostate cancer clinic are eligible.
Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB Clinic, NCI.
Blood samples will be collected after the patient signs the protocol consent form. In general, blood will be collected one time for this study. Extra samples may be requested if the original sample was not enough. The additional sample can range from one to two tubes of blood (approximately 2-3 teaspoons total). Genomic DNA and white blood cells will each be extracted from these samples to be utilized for genotyping and establishment of individual cell lines.
Genetic variance will be correlated with prostate cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e. histological tumor grade).
Healthy controls will not be compared and no correlations will be made with prostate cancer susceptibility.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Collection of Blood From Patients With Prostate Cancer|
|Actual Study Start Date :||February 28, 2007|
blood samples from patients with diagnosed prostate cancer
- Acquisition and longitudinal analysis of genomic DNA from patients with prostate cancer [ Time Frame: Study duration ]Acquisition and longitudinal analysis of genomic DNA from patients with prostate cancer to aid in understanding the mechanisms of prostate carcinogenesis and progression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00923221
|Contact: William D Figg, Pharm.D.||(240) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937|
|Principal Investigator:||William D Figg, Pharm.D.||National Cancer Institute (NCI)|